BR112022015002A2 - Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico - Google Patents

Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico

Info

Publication number
BR112022015002A2
BR112022015002A2 BR112022015002A BR112022015002A BR112022015002A2 BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2 BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2
Authority
BR
Brazil
Prior art keywords
gamma
alpha
ligand
disease
patient
Prior art date
Application number
BR112022015002A
Other languages
English (en)
Portuguese (pt)
Inventor
J Dower William
C Needels Michael
W Barrett Ronald
V Bakker Alice
E Cwirla Steven
Original Assignee
Medikine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medikine Inc filed Critical Medikine Inc
Publication of BR112022015002A2 publication Critical patent/BR112022015002A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022015002A 2020-02-03 2021-02-03 Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico BR112022015002A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969432P 2020-02-03 2020-02-03
US202063041158P 2020-06-19 2020-06-19
PCT/US2021/016361 WO2021158623A1 (en) 2020-02-03 2021-02-03 IL-7Rαγc BINDING COMPOUNDS

Publications (1)

Publication Number Publication Date
BR112022015002A2 true BR112022015002A2 (pt) 2022-12-06

Family

ID=77200524

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015002A BR112022015002A2 (pt) 2020-02-03 2021-02-03 Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico

Country Status (12)

Country Link
US (2) US11746139B2 (cg-RX-API-DMAC7.html)
EP (1) EP4100427A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023514128A (cg-RX-API-DMAC7.html)
KR (1) KR20220139918A (cg-RX-API-DMAC7.html)
CN (1) CN115315435A (cg-RX-API-DMAC7.html)
AU (2) AU2021217353A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015002A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166816A1 (cg-RX-API-DMAC7.html)
IL (1) IL295304A (cg-RX-API-DMAC7.html)
MX (1) MX2022009390A (cg-RX-API-DMAC7.html)
TW (2) TWI812918B (cg-RX-API-DMAC7.html)
WO (1) WO2021158623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210055694A (ko) 2018-08-06 2021-05-17 메디카인 인코포레이티드 Il-2 수용체 결합 화합물
CA3160466A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
MX2022005411A (es) 2019-11-05 2022-08-10 Medikine Inc COMPUESTOS DE UNIÓN A IL-2RßYC.
US11746139B2 (en) * 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
AU2021217959A1 (en) * 2020-02-03 2022-08-18 Medikine, Inc. IL-7Rα binding compounds
EP4240394A4 (en) * 2020-11-04 2024-10-23 Medikine, Inc. IL-2R BETA-GAMMA C-BINDING COMPOUNDS AND USES THEREOF
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
US20240101959A1 (en) 2022-09-06 2024-03-28 Medikine, Inc. Use of il-2r-beta-gamma agonist peptides in cell manufacturing
US20240100159A1 (en) 2022-09-06 2024-03-28 Medikine, Inc. Use of il-7r-alpha-gamma agonist peptides in cell manufacturing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP1828231A2 (en) 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
US20120210458A9 (en) 2009-02-27 2012-08-16 Yongwei Cao Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Thereof
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
EP2649094B1 (en) * 2010-12-10 2016-04-27 University of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11053293B2 (en) 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN110392695B (zh) * 2016-12-09 2021-02-02 Ose免疫疗法 针对cd127的抗体和多肽
CN110177564A (zh) 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
KR20210055694A (ko) 2018-08-06 2021-05-17 메디카인 인코포레이티드 Il-2 수용체 결합 화합물
WO2020247388A2 (en) 2019-06-03 2020-12-10 Medikine, Inc. Il-2alpha receptor subunit binding compounds
MX2022005411A (es) 2019-11-05 2022-08-10 Medikine Inc COMPUESTOS DE UNIÓN A IL-2RßYC.
US20220119492A1 (en) 2019-11-05 2022-04-21 Medikine, Inc. Il-2r-beta-gamma binding compounds and uses thereof
CA3160466A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
AU2021217959A1 (en) 2020-02-03 2022-08-18 Medikine, Inc. IL-7Rα binding compounds
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
EP4240394A4 (en) 2020-11-04 2024-10-23 Medikine, Inc. IL-2R BETA-GAMMA C-BINDING COMPOUNDS AND USES THEREOF
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins

Also Published As

Publication number Publication date
KR20220139918A (ko) 2022-10-17
MX2022009390A (es) 2022-11-16
US20230357358A1 (en) 2023-11-09
TW202342505A (zh) 2023-11-01
AU2021217353A1 (en) 2022-08-25
CN115315435A (zh) 2022-11-08
CA3166816A1 (en) 2021-08-12
IL295304A (en) 2022-10-01
JP2023514128A (ja) 2023-04-05
WO2021158623A1 (en) 2021-08-12
EP4100427A4 (en) 2024-01-17
US11746139B2 (en) 2023-09-05
AU2024201860A1 (en) 2024-05-16
US11965015B2 (en) 2024-04-23
TWI812918B (zh) 2023-08-21
TW202144390A (zh) 2021-12-01
US20210253670A1 (en) 2021-08-19
EP4100427A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
BR112022008744A2 (pt) Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
CL2024003895A1 (es) Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso.
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
JOP20200315B1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
AR122018A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112022024483A2 (pt) Métodos para tratar mieloma múltiplo
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BR112016002496A2 (pt) composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
EA201500373A1 (ru) Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор
ECSP066833A (es) Compuestos heterocíclicos anticitocina
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
CO2024003967A2 (es) Proteínas que se unen a nkg2d, cd16 y baff-r
MX2022009390A (es) Compuestos de unión a il-7r¿¿c.
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.